Annual Report 2024
Department of Pathology and Clinical Laboratories
Genichiro Ishii, Michiko Nagamine, Tetsuro Taki, Yukiko Sasahara, Motohiro Kojima, Shingo Sakashita, Naoya Sakamoto, Takeshi Kuwata, Hirohiko Miyake, Satoshi Fujii, Reiko Watanabe, Hiroki Imada, Hiroko Hashimoto, Aya Endo, Misato Ohhashi, Yuduri Hasegawa, Yumiko Follett
Introduction
Clinical practice in the Department of Pathology and Clinical Laboratories is conducted in accordance with the international standards of ISO 15189 and the College of American Pathologists (CAP) accreditation, ensuring quality assurance and reliability.
The Team and What We Do
In 2023, the Department performed 14,662 biopsy diagnoses, 3,740 surgical specimen diagnoses, 6,065 cytological diagnoses, and 4 autopsy diagnoses, with the results summarized in Table 1. In close collaboration with each clinical department, we regularly hold clinicopathological conferences (CPCs) to enhance the quality of clinical decision-making and to promote research activities. In addition, organ-specific pathologists consistently participate in the expert panels for genomic panel testing, thereby contributing actively to the establishment of a robust foundation for personalized medicine.
Table 1. Number of pathology and cytology samples examined in the Department of Pathology in 2024
Our department develops hypotheses derived from daily clinical practice—so-called clinical questions (CQs)—and advances them into scholarly publications. We are also engaged in pioneering studies aimed at innovating diagnostic pathology, including the development of novel diagnostic methods using mathematical modeling. Furthermore, several staff members concurrently serve in the Exploratory Oncology Research & Clinical Trial Center (Divisions of Clinical Tumor Pathology and Translational Pathology & Clinical Testing), conducting multidisciplinary research to elucidate the biological basis of cancer, establish new diagnostic methodologies, and develop novel therapeutic strategies. As an infrastructure to support these activities, we operate a biobank program, preserving plasma, DNA/RNA from peripheral blood mononuclear cells, and frozen surgical specimens, thereby making substantial contributions to the advancement of both internal and external research. Moreover, in studies such as the TITANIA study, the SCRUM-Japan project, and other investigator-initiated research, we provide critical support through the collection of unfixed specimens, as well as the preparation of residual tissue blocks and histological sections, in close collaboration with laboratory technologists, thereby sustaining and advancing translational research.
Research Activities
The following are this year's major research results.
1. In EGFR-mutated lung adenocarcinoma, solid-predominant histology and high podoplanin expression in CAFs were associated with resistance to osimertinib, suggesting potential markers to guide treatment selection.
2. In early esophageal cancer, AI-based analysis showed invasive regions had significantly greater vessel number and caliber and higher red-blood-cell content than noninvasive areas, implicating vascular remodeling in invasion.
3. In lung squamous cell carcinoma, an AI-derived spatial tumor–stroma distribution index (STSDI) was strongly associated with outcomes; low STSDI independently predicted recurrence and disease-specific mortality.
4. In gastric cancer, quantitative RNA-ISH of stromal fibroblast GREM1 showed that high expression correlated with advanced stage and lymphovascular invasion, indicating a potential independent adverse prognostic factor.
5. In 148 patients with cT1–2N0 tongue squamous cell carcinoma, an integrated model combining AI-derived histopathology with clinicopathologic variables accurately predicted nodal recurrence; recurrent cases featured mixed tumor, inflammatory, and muscle components.
6. In 296 EGFR-mutated lung adenocarcinomas, IASLC grade 3 was an independent adverse prognostic factor and was associated with a TME enriched for pro-tumorigenic CD204+ TAMs and PDPN+ CAFs.
7. In 198 lung squamous cell carcinomas, micronests in cancer stroma (MICS) were present in 28.8% and constituted an independent adverse prognostic factor; MICS cells showed decreased E-cadherin and increased GLUT-1 expression, underscoring biological significance.
8. In 239 resected NSCLCs, a mathematical model quantified spatial intratumoral heterogeneity of PD-L1; high heterogeneity was linked to significantly higher recurrence and served as an independent adverse prognostic factor, validated in an independent cohort—supporting this framework for spatial protein analysis.
9. Using 114 OPSCC cases, an AI model predicted p16 status; analysis of attention patches and CycleGAN-based image translation highlighted differences in nuclear size/density and intercellular bridges, improving interpretability and supporting clinical deployment of morphology-based pathology AI.
Clinical Trials
Pathological testing strengthens the quality control and quality assurance of clinical tests performed in the NCCHE's clinical trials.
Education
Our department is committed to training the next generation of pathologists and clinicians. We hold weekly meetings with residents to encourage them to raise clinical questions (CQs) from daily practice and to guide them through the process, from forming a hypothesis to publishing their work. Pathology and clinical residents also receive direct training in diagnostic pathology, supported by weekly case conferences and research presentations that help improve both analytical and presentation skills. In addition, we provide academic supervision for physicians at our hospital who are enrolled in the doctoral program at Juntendo University, assisting them with dissertation writing and research publication. Some of our staff members also teach at the Graduate School of Frontier Sciences, The University of Tokyo, where they guide master’s students in pathology research. Through these activities, we aim not only to train specialists in diagnostic pathology but also to develop physician-scientists who can connect clinical medicine with basic research.
Future Prospects
Our top priority is to maintain accreditation from the College of American Pathologists (CAP), ensuring ongoing improvements in diagnostic accuracy and quality. At the same time, we are working on the development of laboratory-developed tests (LDTs) that meet clinical needs and actively adopting new diagnostic methods, with the goal of creating innovative and practical approaches guided by the principle of patient first. Building on our strength in using pathological specimens, we are also expanding translational research that aims to clarify the fundamental biology of cancer and support the development of new treatments. These efforts are designed to bring research findings back to clinical practice in a meaningful way. By strengthening the combined framework of education, clinical service, and research, our department strives to fulfill its social mission in pathology while achieving sustainable growth and continued excellence.
List of papers published in 2024
Journal
1. Kojima N, Nishino S, Sasahara Y, Taki T, Imada H, Miyoshi T, Watanabe SI, Ishii G, Yatabe Y, Mori T, Yoshida A. Inflammatory spindle cell PEComa of the lung with YAP1::TFE3 fusion: a report of two cases and a potential relationship with clear cell stromal tumour. Histopathology, 86:365-372, 2025
2. Umemura S, Udagawa H, Ikeda T, Murakami H, Daga H, Toyozawa R, Kozuki T, Sakakibara-Konishi J, Ohe Y, Morise M, Kato T, Shingyoji M, Hara S, Furuya N, Teranishi S, Takata S, Miyamoto S, Nakachi I, Wakabayashi M, Nomura S, Sato A, Ishii G, Tsuchihara K, Sugiyama E, Kirita K, Sakai T, Shibata Y, Izumi H, Nosaki K, Zenke Y, Matsumoto S, Yoh K, Niho S, Goto K. Clinical Significance of a Prospective Large Genomic Screening for SCLC: The Genetic Classification and a Biomarker-Driven Phase 2 Trial of Gedatolisib. Journal of thoracic oncology, 20:177-193, 2025
3. Oda S, Kuno H, Fujita T, Hiyama T, Kotani D, Kadota T, Sakashita S, Kobayashi T. Clinical usefulness of four-dimensional dynamic ventilation CT for borderline resectable locally advanced esophageal cancer. Japanese journal of radiology, 43:434-444, 2025
4. Jubashi A, Nakayama I, Koganemaru S, Sakamoto N, Oda S, Matsubara Y, Miyashita Y, Sato S, Ushiyama S, Kobayashi A, Okazaki U, Okemoto D, Yamamoto K, Mishima S, Kotani D, Kawazoe A, Hashimoto T, Nakamura Y, Kuboki Y, Bando H, Kojima T, Yoshino T, Miyaaki H, Nakao K, Shitara K. Prognostic and predictive factors for the efficacy and safety of trastuzumab deruxtecan in HER2-positive gastric or gastroesophageal junction cancer. Gastric cancer, 28:63-73, 2025
5. Tomi Y, Kinoshita T, Yura M, Sakamoto N, Fujita T, Tokunaga M, Kinugasa Y. Accuracy of the preoperative estimation of esophageal invasion length of adenocarcinoma of the esophagogastric junction and its discrepancy with the pathological measurement. Surgery today, 55:768-777, 2025
6. Oi H, Taki T, Kuroe T, Sakamoto N, Sakashita S, Kojima M, Sugiyama E, Umemura S, Sakai T, Izumi H, Zenke Y, Matsumoto S, Yoh K, Ishii M, Tsuboi M, Goto K, Ishii G. NETosis in pulmonary pleomorphic carcinoma. Cancer science, 116:524-532, 2025
7. Kajiyama D, Fujiwara N, Shigeno T, Sato K, Yamaguchi M, Sakashita S, Daiko H, Fujita T. Impact of Lymphatic and Venous Invasion Patterns on Postoperative Prognosis and Distant Metastasis in Esophageal Squamous Cell Carcinoma After Preoperative Chemotherapy. Annals of surgical oncology, 32:860-871, 2025
8. Miura R, Ono A, Nakahara H, Shirane Y, Yamaoka K, Fujii Y, Uchikawa S, Fujino H, Murakami E, Kawaoka T, Miki D, Tsuge M, Kishi T, Ohishi W, Sakamoto N, Arihiro K, Hayes CN, Oka S. Serum IL-6 concentration is a useful biomarker to predict the efficacy of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma. Journal of gastroenterology, 60:328-339, 2025
9. Abe H, Kuwata T, Kushima R, Ushiku T. Nationwide survey on HER2 and PD-L1 testing practices in gastric cancer across Japan. Gastric cancer, 28:294-300, 2025
10. Sakai SA, Saeki K, Chi S, Hamaya Y, Du J, Nakamura M, Hojo H, Kojima T, Nakamura Y, Bando H, Kojima M, Suzuki A, Suzuki Y, Akimoto T, Tsuchihara K, Haeno H, Yamashita R, Kageyama SI. Mathematical Modeling Predicts Optimal Immune Checkpoint Inhibitor and Radiotherapy Combinations and Timing of Administration. Cancer immunology research, 13:353-364, 2025
11. Urabe A, Adachi M, Sakamoto N, Kojima M, Ishikawa S, Ishii G, Yano T, Sakashita S. Deep learning detected histological differences between invasive and non-invasive areas of early esophageal cancer. Cancer science, 116:824-834, 2025
12. Nagata H, Kinoshita T, Sakashita S, Kojima M, Taki T, Kuwata T, Yura M, Shitara K, Ishii G, Sakamoto N. Area of Residual Tumor Measurement After Preoperative Chemotherapy as an Objective and Quantitative Method for Predicting the Prognosis of Gastric Cancer: A Single-Center Retrospective Study. World journal of surgery, 49:717-726, 2025
13. Sasaki T, Oda S, Kuno H, Hiyama T, Taki T, Takahashi S, Ishii G, Tsuboi M, Kobayashi T. Potential of spectral imaging generated by contrast-enhanced dual-energy CT for lung cancer histopathological classification - A preliminary study. European journal of radiology open, 14:100628, 2025
14. Imai M, Nakamura Y, Shin S, Okamoto W, Kato T, Esaki T, Kato K, Komatsu Y, Yuki S, Masuishi T, Nishina T, Sawada K, Sato A, Kuwata T, Yamashita R, Fujisawa T, Bando H, Ock CY, Fujii S, Yoshino T. Artificial Intelligence-Powered Human Epidermal Growth Factor Receptor 2 and Tumor Microenvironment Analysis in Human Epidermal Growth Factor Receptor 2-Amplified Metastatic Colorectal Cancer: Exploratory Analysis of Phase II TRIUMPH Trial. JCO precision oncology, 9:e2400385, 2025
15. Minamide T, Minakata N, Yamashita R, Sakashita S, Yoda Y, Ohashi A, Aoshima M, Kobayashi S, Yano T. Oxygen saturation imaging elucidates tumor heterogeneity in gastric cancer. DEN open, 5:e70077, 2025
16. Uehara Y, Izumi H, Taki T, Sakai T, Udagawa H, Sugiyama E, Umemura S, Zenke Y, Matsumoto S, Yoh K, Kubota S, Aokage K, Sakamoto N, Sakashita S, Kojima M, Nagamine M, Hosomi Y, Tsuboi M, Goto K, Ishii G. Solid Predominant Histology and High Podoplanin Expression in Cancer-Associated Fibroblast Predict Primary Resistance to Osimertinib in EGFR-Mutated Lung Adenocarcinoma. JTO clinical and research reports, 6:100779, 2025
17. Sasaki T, Kuno H, Nomura K, Muramatsu Y, Aokage K, Samejima J, Taki T, Goto E, Wakabayashi M, Furuya H, Taguchi H, Kobayashi T. CZT-based photon-counting-detector CT with deep-learning reconstruction: image quality and diagnostic confidence for lung tumor assessment. Japanese journal of radiology, 2025
18. Takei S, Kotani D, Laliotis G, Sato K, Fujiwara N, Kawazoe A, Hashimoto T, Mishima S, Nakayama I, Nakamura Y, Bando H, Kuboki Y, Sakashita S, Spickard E, George GV, Dutta P, Sharma S, Malhotra M, Sethi H, Jurdi A, Liu MC, Yoshino T, Shitara K, Kojima T, Fujita T. Circulating Tumor DNA Assessment to Predict Risk of Recurrence after Surgery in Patients with Locally Advanced Esophageal Squamous Cell Carcinoma: A Prospective Observational Study. Annals of surgery, 2025
19. Niimi T, Samejima J, Wakabayashi M, Miyoshi T, Tane K, Aokage K, Taki T, Nakai T, Ishii G, Kikuchi A, Yoshioka E, Yokose T, Ito H, Tsuboi M. Ten-year follow-up outcomes of limited resection trial for radiologically less-invasive lung cancer. Japanese journal of clinical oncology, 54:479-488, 2024
20. Oka S, Tanaka S, Kajiwara Y, Saito S, Fukunaga Y, Takamatsu M, Kawachi H, Hotta K, Ikematsu H, Kojima M, Saito Y, Yamada M, Kanemitsu Y, Sekine S, Nagata S, Yamada K, Kobayashi N, Ishihara S, Saitoh Y, Matsuda K, Togashi K, Komori K, Ishiguro M, Kuwai T, Okuyama T, Ohuchi A, Ohnuma S, Sakamoto K, Sugai T, Katsumata K, Matsushita HO, Yamano HO, Eda H, Uraoka T, Akimoto N, Kobayashi H, Sugihara K, Ueno H. Treatment Decision for Locally Resected T1 Colorectal Carcinoma-Verification of the Japanese Guideline Criteria for Additional Surgery Based on Long-Term Clinical Outcomes. The American journal of gastroenterology, 119:2019-2027, 2024
21. Hashimoto T, Nakamura Y, Mishima S, Nakayama I, Kotani D, Kawazoe A, Kuboki Y, Bando H, Kojima T, Iida N, Shibuki T, Imai M, Fujisawa T, Nagamine M, Sakamoto N, Kuwata T, Yoshino T, Shitara K. Whole-transcriptome sequencing in advanced gastric or gastroesophageal cancer: A deep dive into its clinical potential. Cancer science, 115:1622-1633, 2024
22. Nagasaki Y, Taki T, Nomura K, Tane K, Miyoshi T, Samejima J, Aokage K, Ohtani-Kim SJ, Kojima M, Sakashita S, Sakamoto N, Ishikawa S, Suzuki K, Tsuboi M, Ishii G. Spatial intratumor heterogeneity of programmed death-ligand 1 expression predicts poor prognosis in resected non-small cell lung cancer. Journal of the National Cancer Institute, 116:1158-1168, 2024
23. Sakashita M, Motoi N, Yamamoto G, Gambe E, Suzuki M, Yoshida Y, Watanabe SI, Takazawa Y, Aoki K, Ochiai A, Sakashita S. An algorithm-based technique for counting mitochondria in cells using immunohistochemical staining of formalin-fixed and paraffin-embedded sections. Journal of cancer research and clinical oncology, 150:172, 2024
24. Miyasaka Y, Hiyama T, Kuno H, Shinozaki T, Tomioka T, Sakashita S, Kobayashi T. Imaging of salivary gland cancers derived from a sublingual gland herniated into the submandibular space: a report of three cases. Neuroradiology, 66:931-935, 2024
25. Suzuki Y, Hasegawa H, Mori T, Teramura K, Tsukada Y, Sasaki T, Kojima M, Ito M. Cytological Analysis of the Surgical Field During Transanal Total Mesorectal Excision for Rectal Cancer: A Prospective Study. Diseases of the colon and rectum, 67:1009-1017, 2024
26. Goto E, Taki T, Nomura K, Miyakami Y, Miyoshi T, Tane K, Samejima J, Aokage K, Nagamine M, Sakashita S, Sakamoto N, Kojima M, Suzuki K, Tsuboi M, Ishii G. Clinicopathological differences between EGFR mutated and EGFR wild-type lung adenocarcinoma with papillary predominant pattern. Lung cancer (Amsterdam, Netherlands), 192:107830, 2024
27. Habu T, Kumagai S, Bando H, Fujisawa T, Mishima S, Kotani D, Nakamura M, Hojo H, Sakashita S, Kinoshita T, Yano T, Mitsunaga S, Nishikawa H, Koyama S, Kojima T. Definitive chemoradiotherapy induces T-cell-inflamed tumor microenvironment in unresectable locally advanced esophageal squamous cell carcinoma. Journal of gastroenterology, 59:798-811, 2024
28. Tsukada Y, Bando H, Inamori K, Wakabayashi M, Togashi Y, Koyama S, Kotani D, Yuki S, Komatsu Y, Homma S, Taketomi A, Uemura M, Kato T, Fukui M, Nakamura N, Kojima M, Kawachi H, Kirsch R, Yoshida T, Sato A, Nishikawa H, Ito M, Yoshino T. Three-year outcomes of preoperative chemoradiotherapy plus nivolumab in microsatellite stable and microsatellite instability-high locally advanced rectal cancer. British journal of cancer, 131:283-289, 2024
29. Hoshi Y, Enokida T, Tamura S, Nakashima T, Okano S, Fujisawa T, Sato M, Wada A, Tanaka H, Takeshita N, Tanaka N, Onaga R, Kishida T, Uryu H, Sakashita S, Asakage T, Tahara M. Efficacy of anti-PD-1 monotherapy for recurrent or metastatic olfactory neuroblastoma. Frontiers in oncology, 14:1379013, 2024
30. Tamaru Y, Kuwai T, Kajiwara Y, Oka S, Saito S, Fukunaga Y, Kawachi H, Takamatsu M, Hotta K, Ikematsu H, Kojima M, Saito Y, Kanemitsu Y, Yamada M, Sekine S, Tanaka S, Nagata S, Nakamura T, Yamada K, Konno M, Ishihara S, Saitoh Y, Matsuda K, Togashi K, Komori K, Ishiguro M, Okuyama T, Ohuchi A, Ohnuma S, Sakamoto K, Sugai T, Katsumata K, Matsushita HO, Yamano HO, Nakai K, Uraoka T, Akimoto N, Kobayashi H, Ajioka Y, Sugihara K, Ueno H. Long-Term Outcomes of Additional Surgery After Endoscopic Resection Versus Primary Surgery for T1 Colorectal Cancer. The American journal of gastroenterology, 119:2418-2425, 2024
31. Tsushima T, Sato N, Guo YM, Nakamura H, Kunisada K, Chi SG, Akie K, Takahashi Y, Nakamura S, Shimada K, Ishii G, Minami Y, Yuda J. Richter transformation acquiring PLCG2 mutation during Bruton tyrosine kinase inhibitors treatment. EJHaem, 5:642-645, 2024
32. Kaminuma Y, Nakai T, Aokage K, Taki T, Miyoshi T, Tane K, Samejima J, Miyazaki S, Sakamoto N, Sakashita S, Kojima M, Watanabe R, Tsuboi M, Ishii G. Prognostic significance of micronest in cancer stroma in resected lung squamous cell carcinoma. Human pathology, 150:20-28, 2024
33. Niimi T, Samejima J, Koike Y, Miyoshi T, Tane K, Aokage K, Taki T, Ishii G, Tsuboi M. A case of lung metastasis from gastric cancer presenting as ground-glass opacity dominant nodules. Journal of cardiothoracic surgery, 19:365, 2024
34. Ishii G. New insights into cancer pathology learned from the dynamics of cancer-associated fibroblasts. Pathology international, 74:493-507, 2024
35. Kubota S, Taki T, Miyoshi T, Tane K, Samejima J, Aokage K, Wakabayashi M, Nomura K, Nagamine M, Kojima M, Sakashita S, Sakamoto N, Tsuboi M, Ishii G. Prognostic value of the international association for the study of lung cancer grading system and its association with the tumor microenvironment in stage I EGFR-muted lung adenocarcinoma. European journal of cancer (Oxford, England : 1990), 207:114184, 2024
36. Hashimoto T, Nakamura Y, Fujisawa T, Imai M, Shibuki T, Iida N, Ozaki H, Nonomura N, Morizane C, Iwata H, Okano S, Yamagami W, Yamazaki N, Kadowaki S, Taniguchi H, Ueno M, Boku S, Oki E, Komatsu Y, Yuki S, Makiyama A, Otsuka T, Hara H, Okano N, Nishina T, Sakamoto Y, Miki I, Kobayashi S, Yuda J, Kageyama SI, Nagamine M, Sakashita S, Sakamoto N, Yamashita R, Koga Y, Bando H, Ishii G, Kuwata T, Park WY, Ohtsu A, Yoshino T. The SCRUM-MONSTAR Cancer-Omics Ecosystem: Striving for a Quantum Leap in Precision Medicine. Cancer discovery, 14:2243-2261, 2024
37. Fassan M, Kuwata T, Matkowskyj KA, Röcken C, Rüschoff J. Claudin-18.2 Immunohistochemical Evaluation in Gastric and Gastroesophageal Junction Adenocarcinomas to Direct Targeted Therapy: A Practical Approach. Modern pathology, 37:100589, 2024
38. Fukuda M, Mukohara T, Kuwata T, Sunami K, Naito Y. Efficacy of Trametinib in Neurofibromatosis Type 1-Associated Gastrointestinal Stromal Tumors: A Case Report. JCO precision oncology, 8:e2300649, 2024
39. Adachi M, Taki T, Kojima M, Sakamoto N, Matsuura K, Hayashi R, Tabuchi K, Ishikawa S, Ishii G, Sakashita S. Predicting lymph node recurrence in cT1-2N0 tongue squamous cell carcinoma: collaboration between artificial intelligence and pathologists. The journal of pathology. Clinical research, 10:e12392, 2024
40. Iida N, Imai M, Okamoto W, Kato T, Esaki T, Kato K, Komatsu Y, Yuki S, Masuishi T, Nishina T, Ebi H, Taniguchi H, Nonomura N, Sunakawa Y, Shiozawa M, Yamazaki K, Boku S, Bando H, Shiraishi Y, Kobayashi M, Goto H, Sato A, Fujii S, Yoshino T, Nakamura Y. Novel ERBB2 Variant Potentially Associated with Resistance against Anti-HER2 Monoclonal Antibody-Based Therapy in ERBB2-Amplified Metastatic Colorectal Cancer. Clinical cancer research, 30:4167-4178, 2024
41. Kitaoka T, Harada K, Sakashita S, Kojima M, Taki T, Kuwata T, Kinoshita T, Futakuchi M, Ishii G, Sakamoto N. Quantification of Gremlin 1 throughout the tumor stroma using whole slide imaging and its clinicopathological significance in gastric cancer. Virchows Archiv, 485:1107-1116, 2024
42. Taki T, Koike Y, Adachi M, Sakashita S, Sakamoto N, Kojima M, Aokage K, Ishikawa S, Tsuboi M, Ishii G. A novel histopathological feature of spatial tumor-stroma distribution predicts lung squamous cell carcinoma prognosis. Cancer science, 115:3804-3816, 2024
43. Inaba A, Ikematsu H, Kojima M, Sakamoto N, Wakabayashi M, Sunakawa H, Nakajo K, Murano T, Kadota T, Shinmura K, Yano T. Association between pathological T1 colorectal cancer with lymphoid follicular replacement and risk of lymph node metastasis. Journal of gastroenterology and hepatology, 39:2631-2638, 2024
44. Tanaka H, Koga Y, Sugahara M, Fuchigami H, Ishikawa A, Yamaguchi T, Banba A, Shinozaki T, Matsuura K, Hayashi R, Sakashita S, Yasunaga M, Yano T. Real-Time Fluorescence Monitoring System for Optimal Light Dosage in Cancer Photoimmunotherapy. Pharmaceuticals (Basel, Switzerland), 17:1246, 2024
45. Minakata N, Kadota T, Sakashita S, Inaba A, Sunakawa H, Takashima K, Nakajo K, Murano T, Shinmura K, Yoda Y, Ikematsu H, Fujita T, Kinoshita T, Yano T. Tumor thickness is associated with metastasis in patients with submucosal invasive adenocarcinoma of the esophagogastric junction. Diseases of the esophagus, 37:doae083, 2024
46. Aokage K, Koyama S, Kumagai S, Nomura K, Shimada Y, Yoh K, Wakabayashi M, Fukutani M, Furuya H, Miyoshi T, Tane K, Samejima J, Taki T, Hayashi T, Matsubayashi J, Ishii G, Nishikawa H, Ikeda N, Tsuboi M. Efficacy, Safety, and Influence on the Tumor Microenvironment of Neoadjuvant Pembrolizumab plus Ramucirumab for PD-L1-Positive NSCLC: A Phase II Trial (EAST ENERGY). Clinical cancer research, 30:5584-5592, 2024
47. Takano Y, Suzuki J, Nomura K, Fujii G, Zenkoh J, Kawai H, Kuze Y, Kashima Y, Nagasawa S, Nakamura Y, Kojima M, Tsuchihara K, Seki M, Kanai A, Matsubara D, Kohno T, Noguchi M, Nakaya A, Tsuboi M, Ishii G, Suzuki Y, Suzuki A. Spatially resolved gene expression profiling of tumor microenvironment reveals key steps of lung adenocarcinoma development. Nature communications, 15:10637, 2024
48. Igata Y, Kudo M, Kojima M, Kami S, Aoki K, Satake T, Kobayashi T, Sugimoto M, Kobayashi S, Konishi M, Gotohda N. Conversion surgery after gemcitabine and cisplatin plus durvalumab for advanced intrahepatic cholangiocarcinoma: A case report. World journal of clinical cases, 12:6721-6727, 2024
49. Yoshimoto M, Washiyama K, Ohnuki K, Doi A, Inokuchi M, Kojima M, Miller BW, Yoshii Y, Inaki A, Fujii H. Long-Term Therapeutic Effects of (225)Ac-DOTA-E[c(RGDfK)](2) Induced by Radiosensitization via G2/M Arrest in Pancreatic Ductal Adenocarcinoma. Pharmaceutics, 17:9, 2024